Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 4-part Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 in healthy volunteers and in patients with immune thrombocytopenic purpura

Trial Profile

A 4-part Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 in healthy volunteers and in patients with immune thrombocytopenic purpura

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs M-254 (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Adverse reactions; Proof of concept
  • Sponsors Momenta Pharmaceuticals
  • Most Recent Events

    • 29 Jan 2019 According to a Momenta Pharmaceuticals media release, first subject has been dosed in this study.
    • 04 Oct 2018 According to a Momenta Pharmaceuticals media release, an overview of this trial will be included in a presentation at the live webcast of Momenta Pharmaceuticals of its R and D day which is to be held on 11 Oct 2018.
    • 09 Aug 2018 According to a Momenta Pharmaceuticals media release, the company has successfully completed the IND studies and is expecting to initiate this phase 1/2 study in late 2018 or early 2019, pending regulatory feedback.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top